Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vaccination with autologous dendritic cells pulsed with allogeneic tumour lysate (MelCancerVac) for the treatment of patients with advanced or metastatic non-small cell lung cancer. A phase II study

Trial Profile

Vaccination with autologous dendritic cells pulsed with allogeneic tumour lysate (MelCancerVac) for the treatment of patients with advanced or metastatic non-small cell lung cancer. A phase II study

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Celecoxib; Melanoma vaccine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top